AbCellera Biologics

Valuation $3B

About AbCellera Biologics

AbCellera is an antibody discovery and development company that develops antibody therapeutics to improve patient outcomes.
Founded 2012-01-01
Industry Biotechnology, Medical, Therapeutics
Last Funding Type Grant
Valuation 3
Total Funding $886.98 million dollars
IPO Status

Financial

AbCellera experienced a significant decline in its stock price, dropping by 57%. Analysts have reduced their price target for AbCellera Biologics Inc. to US$12.71. Despite these challenges, insider stock buying reached US$1.61 million. Additionally, AbCellera's Q1 2024 earnings call provided further insights into the company's financial performance. Billionaire Peter Thiel has left AbCellera's board. The company is playing the long game despite current losses, and there are no significant concerns about its cash burn rate.

AbCellera is engaged in the discovery and development of antibody therapeutics, focusing on antibodies that target the spike proteins of SARS-CoV and SARS-CoV-2 for treating or preventing conditions related to SARS or COVID-19. They are also developing anti-CD3 antibodies for diagnosing or treating hyperproliferative or autoimmune disorders. Additionally, AbCellera is working on an antibody competition model to discover binding patterns using hidden variables. These efforts highlight their focus on innovative antibody-based solutions for infectious and autoimmune diseases.

Funding Rounds 11
Number of Lead Investors 4
Total Funding Amount  $886.98 million dollars
Number of Investors 13

Related Angels

Peter Thiel
View profile